Korean Circ J.  2021 Mar;51(3):263-266. 10.4070/kcj.2020.0512.

SGLT2 Inhibitors: the Gift that Keeps on Giving

• Faith Garcia MV
• Han J

• KMID: 2513524
• DOI: http://doi.org/10.4070/kcj.2020.0512

Figure

• 

  Figure 1 Proposed action of SGLT2 inhibition on ischemic heart. The study of Lee et al.10) tested and determined that SGLT2 inhibition directly acts on the heart based on minimizing of infarcted region and apoptotic heart cells and time-dependent action (image was created using https://biorender.com/).SGLT2 = sodium glucose co-transporter 2.

Reference

1. Kim YS, Ahn Y. Benefits of SGLT2 inhibitor: preventing heart failure and beyond. Korean Circ J. 2019; 49:1196–1198. PMID: 31642218.

2. Lehrke M. SGLT2 inhibition: changing what fuels the heart. J Am Coll Cardiol. 2019; 73:1945–1947. PMID: 30999997.

3. Hwang J, Kim DB, Park HJ. Off-target effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitor in cardiovascular disease. Korean Circ J. 2020; 50:458–460. PMID: 32216177.

4. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393:31–39. PMID: 30424892.

5. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117–2128. PMID: 26378978.

6. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377:644–657. PMID: 28605608.

7. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380:347–357. PMID: 30415602.

8. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020; 17:761–772. PMID: 32665641.

9. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381:1995–2008. PMID: 31535829.

10. Lee SY, Lee TW, Park GT, et al. Sodium/glucose co-transporter 2 inhibitor, empagliflozin, alleviated transient expression of SGLT2 after myocardial infarction. Korean Circ J. 2021; 51:251–262.